Brief: Paxmann Says Limb Cryocompression Well-Tolerated In CIPN Study

Paxman AB (publ)

21/10/2025 07:11

Oct 21 (Reuters) - Paxman AB PAX.ST:

SAID ON MONDAY WEARABLE LIMB CRYOCOMPRESSION DEVICE WAS WELL TOLERATED IN PHASE II STUDY IN CLINICAL TRIAL FOR CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY

LIMB CRYOCOMPRESSION CAN BE SAFELY ADMINISTERED WITH CONCOMITANT SCALP COOLING THERAPY AND SHOWS PROMISING DATA IN REDUCING RATES OF TAXANE-BASED CIPN VERSUS HISTORICAL DATA

 Source text for Workspace: nMFN1SNkb3
 Further company coverage: PAX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))